MDGL·NasdaqGS·Healthcare
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
$501.59
↑1.83(0.37%)
Market cap $11.6B
Revenue
$958.4M
↑ 432.1% YoY
Net Income
$-288.3M
↑ 38.1% YoY
Gross Profit
—
Generating analysis for Madrigal Pharmaceuticals, Inc.… this takes ~10 seconds the first time.
Compare
Related companies
Deep Dive
MemberA full investor briefing on Madrigal Pharmaceuticals, Inc. — history, leadership, risks, and outlook.